Search Results
Results found for "Zhan-Guo Gao"
- A robust and Efficient FRET-Based Assay for Cannabinoid Receptor Ligands Discovery.
Indeed, the difference is lower than 1pKi value between both experiments. W.; Wu, Y.; Zhao, S.; Shui, W.; Li, S.; Korde, A.; Laprairie, R. B.; Stahl, E. L.; Ho, J. .; Zhao, Q.; Hanson, M. A.; Bohn, L. M.; Makriyannis, A.; Stevens, R. C.; Liu, Z.-J. -H.; Wu, Y.; Wu, L.; Popov, P.; Benchama, O.; Zvonok, N.; Locke, K.; Qu, L.; Han, G. W.; Iyer, M. J.; Wang, J.; Wu, M.; Katritch, V.; Zhao, S.; Kunos, G.; Bohn, L. M.; Makriyannis, A.; Stevens, R.
- Drug Discovery Pharmacology Principles That Turn Assays Into Real Medicines
agonist responses to a common reference window Accepting that maximal response may be estimated rather than exact In practice, the precise maximal signal matters less than many assume. EC₅₀ Misconceptions Persist Few misunderstandings derail discovery programs faster than misinterpreting Time Matters More Than Potency For decades, discovery teams prioritized potency above all else.
- The Quiet Power of RGS Proteins: Rethinking Pain Pathways through GPCR Biology
despite these targets falling short clinically: “The downstream cascade is probably a little bit weaker than hitting a GPCR... and honestly, like with the trials, they were not really that sufficiently better than
- GPCR Binding Affinity Experiments: Interpreting Data With Confidence as We Head Into 2026
Interpret multi-phase binding curves correctly , recognizing G-protein coupling and kinetic effects rather than Design GPCR binding affinity experiments that tell the truth , ensuring affinity data support—rather than This growth reflects something deeper than metrics: a shared demand for clearer interpretation, stronger
- Chemical Drug Matter : Rethinking the Molecules We Choose to Develop In Drug Discovery
Less than ~15% of higher plant species, <5% of bacterial and fungal species, and only a fraction of marine This was more than trial-and-error. It was early structure-based pharmacology. Dr. expands drug matter beyond the familiar and encourages deliberate exploration of chemical novelty, rather than
- Ever Wondered How Drugs Are Discovered?
unique ability to combine storytelling, real-world experience, and scientific clarity makes this more than
- How Collaboration Drives GPCR Discoveries
chemist who would eventually help his lab visualize receptors in living systems with far more precision than The knockout behaved differently than expected. And when those pieces come together, the field jumps forward faster than any lab could push it alone.
- Optimizing HTRF Assays with Fluorescent Ligands: Time-Resolved Fluorescence in GPCR Research
The donors used in this technique have longer half-lives than other fluorophores (between 300μs–1 ms Terbium, a second-generation donor, is brighter than Europium (10-20 times), which increases sensitivity The donor lanthanum fluorophores are more stable than regular fluorophores and quite resistant to photobleaching
- Dr. GPCR Updates
article GPCR Publication Highlights βCGRP breaks the mold: Distinct signaling patterns reveal it’s more than
- Antibodies That Don’t Block, They Activate: A New Angle on Autoimmunity and GPCRs
.” — Tom Sakmar This makes them more than biomarkers — they’re potential drivers of disease .
- Biased Agonism at the GLP-1 Receptor: A Pathway to Improved Therapeutic Outcomes
Moreover, exendin-P5 has been observed to reduce adipose tissue size more effectively than exendin, suggesting Zhang, H., et al., Autocrine selection of a GLP-1R G-protein biased agonist with potent antidiabetic
- How to Avoid the Most Common Gaps in Your Biotech Pitch
For biotech founders, this is more than a presentation problem. It’s a strategic vulnerability. academic interest to practical significance. 3️⃣ Why it’s different ✅ Differentiation must be more than who you’re building for, why now is the right time, and how your solution fits into something bigger than
- The Hidden Cost of Ambition in Biotech Leadership
. 👉 The problem begins when ambition grows faster than structure. This is where the structural tension begins. 👉 Scientific optionality grows faster than strategic capacity And this is where biotech fundraising begins to feel harder than it should.
- Structural landscape of the Chemokine Receptor system
The chemokine system exhibits great versatility, with more than 50 chemokines interacting with over 20 Currently, there are more than 40 available structures of chemokines and their receptors in the Protein and the intracellular helix 8 move outward from the receptor core to make room for the G-protein (Lu, Zhao et al. 2017, Isaikina, Tsai et al. 2021, Zhang, Chen et al. 2021). its constitutive activity (Yen, Schafer et al. 2022) which is also supported by mutagenesis studies (Han
- Asking Better Questions in Science: A Practical Guide for Emerging Researchers
As JB puts it, the cost of not asking is much higher than the cost of momentary discomfort. This mindset shapes careers far more than publications alone.
- Feeder or trigger – CCR2 as a scavenger and regulator of cell migration
Zhao et al. 2019). Zhao et al. 2019) together with confocal fluorescence microscopy. with CCR2, indicating that β-arrestin regulates scavenging and signaling of CCR1 to a greater extent than
- Integrated GPCR Drug Discovery: A Structured Framework for Modern Programs
DiscoverX Partnership — Tools and Insight for GPCR Drug Discovery Modern GPCR discovery depends on more than DiscoverX , a global provider of GPCR assay platforms and translational biology services covering more than
- Why Biotech Fundraising Fails Due to Intellectual Property Gaps
science well, but not the value capture From an investor's perspective, this creates confusion rather than 👉 IP discussions happen earlier in fundraising conversations 👉 Investors look for alignment rather than Biotech fundraising will favor teams that use intellectual property as a tool for clarity rather than
- The Hidden Operating Cadence That’s Actually Driving Your Biotech
Timeline slips are absorbed as “part of biology” rather than examined as managerial signals. start planning around delays BD and investor messaging drifts Timelines become aspirational rather than
- The Real Cost of Strategic Overload in Biotech
becomes unclear 👉 Capital allocation appears fragmented 👉 The development timeline looks crowded rather than And uncertainty, even when the science is strong, slows biotech fundraising more than most founders expect Saying yes often feels safer than saying no.
- The Moment Biotech Founders Realize the Money Is Gone
. 👉 How long can we operate if fundraising takes longer than expected? visibility fades while the company keeps moving forward , until choices are driven by urgency rather than That shift creates space to act deliberately again, rather than being pushed forward by circumstances
- How System-Level GPCR Thinking Prevents Discovery Failures
Most GPCR programs don’t fail because of weak molecules—they fail because biology behaves differently than Translate potency and efficacy realistically → Recognize when deviations reflect biology rather than
- Enzyme Inhibition Pharmacology: The Hidden Gatekeepers of GPCR Drug Discovery
By visualizing enzymes as dynamic molecular partners rather than static filters, drug discovery scientists Cytochrome P450: Friend, Foe, and FDA Focus No enzyme class is more important—or more unpredictable—than Yet many discovery teams still relegate them to the “ADME” checklist, rather than the strategic design
- Gαs and Gαq/11 protein coupling bias of two AVPR2 mutants (R68W and V162A) that cause nephrogenic di
Recent studies showed that some AVPR2 mutations could cause biased Gαq/11 protein coupling rather than R68W showed bias to coupling with Gαq/11 protein rather than V162A and wild-type receptor.
- Learn about Dr. GPCR Ecosystem!
GPCR is much more than a podcast? Come check out the brand new Dr.
- Biotech Startup Failure: Why Teams Drift Off Course Without a Single Wrong Decision
obvious mistakes , and why preventing that drift requires a different kind of leadership awareness than Founders often sense this as friction rather than failure. Meetings feel heavier. organizationally. 👉 By the time leadership recognizes the gap, correcting course requires far more effort than
- Roles of Focal Adhesion Kinase PTK2 and Integrin αIIbβ3 Signaling in Collagen- and GPVI-Dependent...
The suppressive rather than activating effects of pGRP were confined to blood flow at a high shear rate Blockage of PTK2 or interference of CIB1 no more than slightly affected thrombus formation at a low shear
- Early Stage Biotech Hiring: What Really Holds a Team Together When the Science Starts to Drift
The science evolves, assumptions break, and timelines shift quietly rather than dramatically. The discovery phase stretches longer than planned. The right ones also know when progress matters more than perfection. 👉 These signals are subtle, but
- Using Live-cell High-Content Screening to Characterize CB2 Ligands: Insights From 16 Synthetic Cannabinoids
reporting the % of displacement measured at 1 µ M and the corresponding Ki for those showing a % higher than across all concentrations, indicating that reduced tracer signal was due to receptor occupancy rather than validation in intact cells, the approach provides a richer picture of ligand–receptor interactions than
- When January Looks Different by March: Orthosteric vs. Allosteric Insights from Our Latest AMA
designed as a continuous learning environment — supporting scientific reasoning as programs mature, rather than Misinterpretation does more than delay progress.

























